Literature DB >> 6668158

Phrenic nerve palsy after topical cardiac hypothermia.

A Dajee, J Pellegrini, G Cooper, K Karlson.   

Abstract

Evidence of phrenic nerve paralysis was found in 16 of 172 (9.3%) consecutive adult cardiac surgical patients who survived surgical procedures using topical cardiac hypothermia; two patients had bilateral phrenic nerve paralysis and 14 had left phrenic nerve paralysis. One or more pulmonary complications occurred in 13 of 16 patients (81.3%) with phrenic nerve paralysis while 80 of 156 (56%) had one or more pulmonary complications among patients who had no hypothermic phrenic nerve injury. Average postoperative hospital stay was 13.6 days for patients with left phrenic nerve paralysis, and 22.5 days for patients having bilateral phrenic nerve paralysis. This postoperative complication predominated in males; 15 of 16 (93.8%) of those in our series with phrenic paralysis were males, while 118 of 172 (68.6%) patients were males. Phrenic paralysis did not correlate with the length or degree of systemic hypothermia on cardiopulmonary bypass. No deaths were attributed to phrenic nerve injury. With a minimum of one year follow-up, 12 of 16 patients had return of normal diaphragmatic motion, four had residual paralysis when examined between 12 and 19 months postoperatively.

Entities:  

Mesh:

Year:  1983        PMID: 6668158

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  2 in total

1.  Post-operative respiratory failure due to bilateral phrenic nerve palsy.

Authors:  R W Burgess; A F Boyd; P G Moore; G S Oldfield
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

2.  Early hemi-diaphragmatic plication through a video assisted mini-thoracotomy in postcardiotomy phrenic nerve paresis.

Authors:  Kosmas Tsakiridis; Aikaterini N Visouli; Paul Zarogoulidis; Nikolaos Machairiotis; Christos Christofis; Aikaterini Stylianaki; Nikolaos Katsikogiannis; Andreas Mpakas; Nicolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2012-11       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.